Literature DB >> 30880773

Myricetin ameliorates cytokine-induced migration and invasion of cholangiocarcinoma cells via suppression of STAT3 pathway.

Pattarapon Tuponchai1, Veerapol Kukongviriyapan2, Auemduan Prawan2, Sarinya Kongpetch2, Laddawan Senggunprai2.   

Abstract

AIM OF STUDY: Cholangiocarcinoma (CCA) is an aggressive cancer with considerable metastatic potential. Various cytokines secreted by tumor cells or cells in the tumor environment can promote the metastasis of CCA. The aim of the present study was to investigate the effect of myricetin on the inhibition of cytokine-induced migration and invasion and the associated cellular mechanisms in human CCA cells.
MATERIALS AND METHODS: CCA KKU-100 cells were treated with a pro-inflammatory cytokine mixture consisting of interleukin-6, interferon-γ, and tumor necrosis factor-α. The migratory and invasive ability of KKU-100 cells were determined using a wound-healing assay and transwell invasion assay. The effect of myricetin on cytokine-induced STAT3 activation in CCA cells was determined using Western blot analysis. The real-time polymerase chain reaction was performed to determine messenger RNA expression.
RESULTS: Myricetin significantly inhibited cytokine-induced migration and invasion of KKU-100 cells. Detailed molecular analyses revealed that myricetin suppressed the activation of the STAT3 pathway, evidently by a decrease of the active phospho-STAT3 protein expression after myricetin treatment. The cytokine-mediated upregulation of metastasis- and inflammatory-associated genes, which are downstream genes of STAT3 including the intercellular adhesion molecule-1, matrix metalloproteinase-9, inducible nitric oxide synthase, and cyclo-oxygenase 2 (COX-2), were also significantly abolished by myricetin treatment. Moreover, the anti-migratory and anti-invasive activities of a widely prescribed COX inhibitor, indomethacin, were also revealed.
CONCLUSION: This finding reveals the anti-metastatic effect of myricetin against CCA cells which is mediated partly through suppression of the STAT3 pathway. This compound could be potentially useful as a therapeutic agent against CCA.

Entities:  

Keywords:  Cholangiocarcinoma; STAT3; inflammation; metastasis; myricetin

Mesh:

Substances:

Year:  2019        PMID: 30880773     DOI: 10.4103/jcrt.JCRT_287_17

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  6 in total

1.  Cucurbitacin B Diminishes Metastatic Behavior of Cholangiocarcinoma Cells by Suppressing Focal Adhesion Kinase.

Authors:  Putthaporn Kaewmeesri; Veerapol Kukongviriyapan; Auemduan Prawan; Sarinya Kongpetch; Laddawan Senggunprai
Journal:  Asian Pac J Cancer Prev       Date:  2021-01-01

2.  Derrischalcone suppresses cholangiocarcinoma cells through targeting ROS-mediated mitochondrial cell death, Akt/mTOR, and FAK pathways.

Authors:  Jaroon Wandee; Piyarat Srinontong; Auemduan Prawan; Laddawan Senggunprai; Sarinya Kongpetch; Chavi Yenjai; Veerapol Kukongviriyapan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-06-04       Impact factor: 3.000

3.  Brevilin A induces ROS-dependent apoptosis and suppresses STAT3 activation by direct binding in human lung cancer cells.

Authors:  Muhammad Khan; Amara Maryam; Muhammad Zubair Saleem; Hafiz Abdullah Shakir; Javed Iqbal Qazi; Yongming Li; Tonghui Ma
Journal:  J Cancer       Date:  2020-04-06       Impact factor: 4.207

Review 4.  Myricetin: targeting signaling networks in cancer and its implication in chemotherapy.

Authors:  Zeeshan Javed; Khushbukhat Khan; Jesús Herrera-Bravo; Sajid Naeem; Muhammad Javed Iqbal; Qamar Raza; Haleema Sadia; Shahid Raza; Munir Bhinder; Daniela Calina; Javad Sharifi-Rad; William C Cho
Journal:  Cancer Cell Int       Date:  2022-07-28       Impact factor: 6.429

5.  Homophilic Interaction of CD147 Promotes IL-6-Mediated Cholangiocarcinoma Invasion via the NF-κB-Dependent Pathway.

Authors:  Paweena Dana; Ryusho Kariya; Worachart Lert-Itthiporn; Wunchana Seubwai; Saowaluk Saisomboon; Chaisiri Wongkham; Seiji Okada; Sopit Wongkham; Kulthida Vaeteewoottacharn
Journal:  Int J Mol Sci       Date:  2021-12-16       Impact factor: 5.923

Review 6.  Flavonoids against non-physiologic inflammation attributed to cancer initiation, development, and progression-3PM pathways.

Authors:  Peter Kubatka; Alena Mazurakova; Marek Samec; Lenka Koklesova; Kevin Zhai; Raghad Al-Ishaq; Karol Kajo; Kamil Biringer; Desanka Vybohova; Aranka Brockmueller; Martin Pec; Mehdi Shakibaei; Frank A Giordano; Dietrich Büsselberg; Olga Golubnitschaja
Journal:  EPMA J       Date:  2021-10-06       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.